Cargando…
Beta-blockers in post-acute myocardial infarction patients: Drug prescription patterns from 2018 to Italy’s first wave of the COVID-19 pandemic
Background: Major guidelines recommend the initiation of a beta-blocker therapy after an acute myocardial infarction (AMI). We aimed to map the treatment pathway of beta-blockers for AMI survivors during the first wave of COVID-19 pandemic in Italy and to investigate predictors for treatment non-ini...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768333/ https://www.ncbi.nlm.nih.gov/pubmed/36569305 http://dx.doi.org/10.3389/fphar.2022.1040710 |
_version_ | 1784854142198480896 |
---|---|
author | Olmastroni, Elena Galimberti, Federica Catapano, Alberico L. Tragni, Elena Casula, Manuela |
author_facet | Olmastroni, Elena Galimberti, Federica Catapano, Alberico L. Tragni, Elena Casula, Manuela |
author_sort | Olmastroni, Elena |
collection | PubMed |
description | Background: Major guidelines recommend the initiation of a beta-blocker therapy after an acute myocardial infarction (AMI). We aimed to map the treatment pathway of beta-blockers for AMI survivors during the first wave of COVID-19 pandemic in Italy and to investigate predictors for treatment non-initiation. Methods: Healthcare utilization databases of Lombardy Region were investigated. Subjects aged ≥18 years who were hospitalised with AMI in the period February-March-April of 2018, 2019, and 2020 were included, and followed for 30 days from the discharge date, to investigate whether they presented a first prescription of beta-blockers. A multivariate logistic model was performed to evaluate the effect of several covariates on the probability of not receiving a post-AMI beta-blocker therapy. Results: The cohorts comprised 2259, 2383, and 1932 individuals who were hospitalised with AMI in the 3-month period in 2018, 2019, and 2020, respectively. Overall in 2020, about 58–60% of individuals with AMI received a prescription of beta-blockers within 1 month after the discharge. A continuous decreasing trend over time was observed. Men were 30% more likely to start the treatment than women, increasing age was associated with significant increasing probability of not receiving a post-infarction beta-blocker therapy, while having received an antihypertensive or lipid-lowering treatment, or having been hospitalized for heart failure prior to the AMI hospitalization reduced the likelihood of not being treated with beta-blockers. Conclusion: The initiation of beta-blocker treatment after AMI remains an under-prescribed practice, that does not seem to have been further affected by the first wave of the COVID-19 pandemic. |
format | Online Article Text |
id | pubmed-9768333 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97683332022-12-22 Beta-blockers in post-acute myocardial infarction patients: Drug prescription patterns from 2018 to Italy’s first wave of the COVID-19 pandemic Olmastroni, Elena Galimberti, Federica Catapano, Alberico L. Tragni, Elena Casula, Manuela Front Pharmacol Pharmacology Background: Major guidelines recommend the initiation of a beta-blocker therapy after an acute myocardial infarction (AMI). We aimed to map the treatment pathway of beta-blockers for AMI survivors during the first wave of COVID-19 pandemic in Italy and to investigate predictors for treatment non-initiation. Methods: Healthcare utilization databases of Lombardy Region were investigated. Subjects aged ≥18 years who were hospitalised with AMI in the period February-March-April of 2018, 2019, and 2020 were included, and followed for 30 days from the discharge date, to investigate whether they presented a first prescription of beta-blockers. A multivariate logistic model was performed to evaluate the effect of several covariates on the probability of not receiving a post-AMI beta-blocker therapy. Results: The cohorts comprised 2259, 2383, and 1932 individuals who were hospitalised with AMI in the 3-month period in 2018, 2019, and 2020, respectively. Overall in 2020, about 58–60% of individuals with AMI received a prescription of beta-blockers within 1 month after the discharge. A continuous decreasing trend over time was observed. Men were 30% more likely to start the treatment than women, increasing age was associated with significant increasing probability of not receiving a post-infarction beta-blocker therapy, while having received an antihypertensive or lipid-lowering treatment, or having been hospitalized for heart failure prior to the AMI hospitalization reduced the likelihood of not being treated with beta-blockers. Conclusion: The initiation of beta-blocker treatment after AMI remains an under-prescribed practice, that does not seem to have been further affected by the first wave of the COVID-19 pandemic. Frontiers Media S.A. 2022-12-07 /pmc/articles/PMC9768333/ /pubmed/36569305 http://dx.doi.org/10.3389/fphar.2022.1040710 Text en Copyright © 2022 Olmastroni, Galimberti, Catapano, Tragni and Casula. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Olmastroni, Elena Galimberti, Federica Catapano, Alberico L. Tragni, Elena Casula, Manuela Beta-blockers in post-acute myocardial infarction patients: Drug prescription patterns from 2018 to Italy’s first wave of the COVID-19 pandemic |
title | Beta-blockers in post-acute myocardial infarction patients: Drug prescription patterns from 2018 to Italy’s first wave of the COVID-19 pandemic |
title_full | Beta-blockers in post-acute myocardial infarction patients: Drug prescription patterns from 2018 to Italy’s first wave of the COVID-19 pandemic |
title_fullStr | Beta-blockers in post-acute myocardial infarction patients: Drug prescription patterns from 2018 to Italy’s first wave of the COVID-19 pandemic |
title_full_unstemmed | Beta-blockers in post-acute myocardial infarction patients: Drug prescription patterns from 2018 to Italy’s first wave of the COVID-19 pandemic |
title_short | Beta-blockers in post-acute myocardial infarction patients: Drug prescription patterns from 2018 to Italy’s first wave of the COVID-19 pandemic |
title_sort | beta-blockers in post-acute myocardial infarction patients: drug prescription patterns from 2018 to italy’s first wave of the covid-19 pandemic |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768333/ https://www.ncbi.nlm.nih.gov/pubmed/36569305 http://dx.doi.org/10.3389/fphar.2022.1040710 |
work_keys_str_mv | AT olmastronielena betablockersinpostacutemyocardialinfarctionpatientsdrugprescriptionpatternsfrom2018toitalysfirstwaveofthecovid19pandemic AT galimbertifederica betablockersinpostacutemyocardialinfarctionpatientsdrugprescriptionpatternsfrom2018toitalysfirstwaveofthecovid19pandemic AT catapanoalbericol betablockersinpostacutemyocardialinfarctionpatientsdrugprescriptionpatternsfrom2018toitalysfirstwaveofthecovid19pandemic AT tragnielena betablockersinpostacutemyocardialinfarctionpatientsdrugprescriptionpatternsfrom2018toitalysfirstwaveofthecovid19pandemic AT casulamanuela betablockersinpostacutemyocardialinfarctionpatientsdrugprescriptionpatternsfrom2018toitalysfirstwaveofthecovid19pandemic |